The Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
The Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Metabolism. 2022 Apr;129:155156. doi: 10.1016/j.metabol.2022.155156. Epub 2022 Jan 29.
Both obesity and type 2 diabetes (T2D) are reported to be highly enriched in hospitalized COVID-19 patients. Due to the close correlation between obesity and T2D, it is important to examine whether obesity and T2D are independently related to COVID-19 hospitalization.
To examine the causal effect of obesity and T2D in hospitalized COVID-19 patients using Mendelian randomization (MR).
This two-sample MR analysis applied genetic markers of obesity identified in the genome wide association study (GWAS) by the GIANT Consortium as instrumental variables (IVs) of obesity; and genetic markers of T2D identified by the DIAGRAM Consortium as IVs of T2D. The MR analysis was performed in hospitalized COVID-19 patient by the COVID-19 Host Genetics Initiative using the MR-Base platform.
All 3 classes of obesity (Class 1/2/3) were shown as the causal risk factors of COVID-19 hospitalization; however, T2D doesn't increase the risk of hospitalization or critically ill COVID-19 as an independent factor.
Obesity, but not T2D, is a primary risk factor of COVID-19 hospitalization.
肥胖症和 2 型糖尿病（T2D）在住院的 COVID-19 患者中均高度富集。由于肥胖症和 T2D 之间存在密切的相关性，因此重要的是要检查肥胖症和 T2D 是否与 COVID-19 住院独立相关。
使用孟德尔随机化（MR）检查住院 COVID-19 患者中肥胖症和 T2D 的因果效应。
本两样本 MR 分析应用了 GIANT 联盟在全基因组关联研究（GWAS）中确定的肥胖症遗传标志物作为肥胖症的工具变量（IVs）；以及 DIAGRAM 联盟确定的 T2D 遗传标志物作为 T2D 的 IVs。该 MR 分析由 COVID-19 宿主遗传学倡议在 COVID-19 宿主遗传学倡议中使用 MR-Base 平台在住院 COVID-19 患者中进行。
所有 3 类肥胖症（1/2/3 类）均显示为 COVID-19 住院的因果风险因素；然而，T2D 不作为独立因素增加住院或重症 COVID-19 的风险。
肥胖症，而不是 T2D，是 COVID-19 住院的主要危险因素。
